ArticleJournal of gastric cancer2017

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.

Charles S Fuchs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.